FAK Inhibition Emerges as a Potential Complementary Treatment Pathway
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this
Submission gap and review time for oncology applications at Swissmedic were significantly reduced by participation in Project Orbis, and approval consensus decisions were increased between…
Thursday, 13 June, 2024 5:00 – 6:30 PM CEST Room Name: Dali 2 Hall IFEMA Madrid Recinto Ferial (Fairgrounds) Av. del Partenón, 5, Barajas, 28042…
R. Wendel Naumann, MD, discusses 2 case studies in platinum-resistant ovarian cancer and the optimal treatment approaches for each patient.
Nature Reviews Cancer – In this Review, Paul et al. provide an overview of therapeutic antibodies as an important modality in cancer therapy today. They…
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary…
Fewer than a third of indications approved with immature survival data showed a statistically significant overall survival benefit after approval. Notable inconsistencies in timing and…
Submission gap and review time for oncology applications at Swissmedic were significantly reduced by participation in Project Orbis, and approval consensus decisions were increased between…
Nina Worel, MD, Medical University of Vienna, Vienna, Austria, discusses the efficacy of allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy, tabelecleucel, in patients with post-transplant lymphoproliferative…